Alcon Stock Rises Following the FDA Approval of TRYPTYR

Alcon (ALC) recently received Food and Drug Administration (“FDA”) approval for its TRYPTYR (acoltremon ophthalmic solution) 0.003%. TRYPTYR is indicated for the treatment of the signs and symptoms of dry eye disease (“DED”). The latest approval is expected to bolster the company’s Vision Care segment. Further, ALC plans to launch TRYPTYR in the United States in the third quarter of 2025. Likely Trend of ALC Stock Following the NewsFollowing the announcement, shares of Alcon edged up 2.5% in the after-marke ...